Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 14.92% is 35% below its 5-year average of 22.91%, near the high end of its 5-year range (-153.07%–67.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.11% below its 12-month average of 19.66%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2026 (2026-06-30): 14.92%.
GROSS MARGIN
14.92%
GROSS MARGIN AVG TTM
19.66%
GROSS MARGIN AVG 3Y
26.93%
GROSS MARGIN AVG 5Y
22.91%
GROSS MARGIN AVG 10Y
10.01%
GROSS MARGIN AVG 15Y
0.23%
GROSS MARGIN AVG 20Y
10.78%
CURRENT VS TTM AVG
-24.11%
CURRENT VS 3Y AVG
-44.61%
CURRENT VS 5Y AVG
-34.87%
CURRENT VS 10Y AVG
+49.12%
CURRENT VS 15Y AVG
+6373.41%
CURRENT VS 20Y AVG
+38.36%
SECTOR MEDIAN · HEALTHCARE
39.32%
median of 679 covered companies
CURRENT VS SECTOR MEDIAN
-62.05%
vs the sector median at left
InMed Pharmaceuticals Inc.
Market Cap
$7.31M
Gross Margin
14.92%
TTM Avg
19.66%
3Y Avg
26.93%
5Y Avg
22.91%
Market Cap
$7.26M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$7.13M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$7.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.98M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$7.83M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.31M | 14.92% | 19.66% | 26.93% | 22.91% |
| KALA BIO, Inc. (KALA)vs › | $7.28M | 0.00% | 0.00% | 8.55% | 24.65% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.26M | 0.00% | 0.00% | 4.26% | 4.26% |
| Longeveron Inc. (LGVN)vs › | $7.47M | 69.76% | 72.87% | 54.39% | 49.20% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | 64.28% | 69.38% | 65.33% | 71.21% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | 54.43% | 58.30% | 57.46% | 45.97% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| GT Biopharma, Inc. (GTBP)vs › | $7.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclarion, Inc. (ACON)vs › | $6.66M | -291.27% | -237.54% | -120.88% | -89.07% |
Gross Margin
14.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 14.92% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 3.19% |
| 2025-09-30 | 35.99% |
| 2025-06-30 | 44.20% |
| 2025-03-31 | 13.92% |
| 2024-12-31 | 41.46% |
| 2024-09-30 | 39.02% |
| 2024-06-30 | 36.32% |
| 2024-03-31 | 24.69% |
| 2023-12-31 | 26.14% |
| 2023-09-30 | 2.36% |
| 2023-06-30 | 67.95% |
| 2023-03-31 | 4.83% |
| 2022-12-31 | 27.92% |
| 2022-09-30 | -153.07% |
| 2022-06-30 | 20.43% |
| 2022-03-31 | 12.75% |
| 2021-12-31 | 42.08% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 0.00% |
| 2012-06-30 | 0.00% |
| 2012-03-31 | 0.00% |
| 2011-12-31 | 0.00% |
| 2011-09-30 | 0.00% |
| 2011-06-30 | 14.58% |
| 2011-03-31 | 80.20% |
| 2010-12-31 | 17.48% |
| 2010-09-30 | -64.47% |
| 2010-06-30 | 99.62% |
| 2010-03-31 | 54.62% |
| 2009-12-31 | 5.46% |
| 2009-09-30 | 84.58% |
| 2009-06-30 | 59.06% |
| 2009-03-31 | 74.17% |
| 2008-12-31 | 0.78% |
| 2008-09-30 | 35.70% |
| 2008-06-30 | 19.95% |
| 2008-03-31 | 38.06% |
| 2007-12-31 | 39.53% |
| 2007-09-30 | 25.00% |
| 2007-06-30 | -6.19% |
| 2007-03-31 | 13.54% |
| 2006-12-31 | -71.92% |
| 2006-09-30 | 33.11% |
| 2006-06-30 | 46.28% |
| 2006-03-31 | 22.15% |
| 2005-12-31 | 51.88% |
| 2005-09-30 | 42.08% |
| 2005-06-30 | 18.38% |
| 2005-03-31 | 23.80% |
| 2004-12-31 | 27.22% |
| 2004-09-30 | 36.10% |
| 2004-07-31 | 95.82% |
| 2004-04-30 | 21.94% |
| 2004-01-31 | 31.97% |
| 2003-10-31 | 32.97% |
| 2003-07-31 | 49.20% |
| 2003-04-30 | 63.45% |
| 2003-01-31 | -319.00% |
| 2002-10-31 | 98.14% |
